Do analysts recommend CALT or LEGN?

Legend Biotech has a consensus price target of $60.23, suggesting a potential upside of 72.78%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Legend Biotech 1 Sell rating(s) 3 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.67

Do analysts recommend NNNN or CALT?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, NNNN or CALT?

Anbio Biotechnology has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anbio Biotechnology $8.65M 273.31 $6.40M N/A N/A Calliditas Therapeutics AB (publ) $1.60B 0.74 -$43.96M -$1.85 N/A

Do analysts recommend EWTX or CALT?

Edgewise Therapeutics presently has a consensus price target of $44.22, indicating a potential upside of 34.33%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 1 Sell rating(s) 1 Hold rating(s) 6 Buy rating(s) 1 Strong Buy rating(s) 2.78 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts recommend ERAS or CALT?

Erasca presently has a consensus target price of $20.11, indicating a potential upside of 50.42%. Given Erasca's stronger consensus rating and higher possible upside, equities research analysts clearly believe Erasca is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Erasca 1 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.60 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Do analysts prefer INDV or CALT?

Indivior currently has a consensus price target of $39.33, indicating a potential upside of 3.26%. Given Indivior's stronger consensus rating and higher possible upside, equities analysts clearly believe Indivior is more favorable than Calliditas Therapeutics AB (publ). Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Indivior 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 3.00 Calliditas Therapeutics AB (publ) 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Calliditas Therapeutics AB (publ) (CALT) Competitors

$40.00 0.00 (0.00%)

As of 06/9/2026

Compare

CALT vs. LEGN, NNNN, EWTX, ERAS, and INDV

Should you buy Calliditas Therapeutics AB (publ) stock or one of its competitors? MarketBeat compares Calliditas Therapeutics AB (publ) with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Calliditas Therapeutics AB (publ) include Legend Biotech (LEGN), Anbio Biotechnology (NNNN), Edgewise Therapeutics (EWTX), Erasca (ERAS), and Indivior (INDV). These companies are all part of the "pharmaceutical products" industry.

How does Calliditas Therapeutics AB (publ) compare to Legend Biotech?

Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk and dividends.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Calliditas Therapeutics AB (publ), indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A
Legend Biotech	$1.03B	6.29	-$296.80M	-$0.68	N/A

Legend Biotech has a net margin of -21.98% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Legend Biotech's return on equity of -24.92% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%
Legend Biotech	-21.98%	-24.92%	-14.87%

2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. Comparatively, 70.9% of Legend Biotech shares are owned by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are owned by insiders. Comparatively, 0.0% of Legend Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Legend Biotech has a consensus price target of $60.23, suggesting a potential upside of 72.78%. Given Legend Biotech's stronger consensus rating and higher probable upside, analysts clearly believe Legend Biotech is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Legend Biotech	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market. Comparatively, Legend Biotech has a beta of 0.35, indicating that its stock price is 65% less volatile than the broader market.

In the previous week, Legend Biotech had 5 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 5 mentions for Legend Biotech and 0 mentions for Calliditas Therapeutics AB (publ). Legend Biotech's average media sentiment score of 0.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Legend Biotech is being referred to more favorably in the news media.

Company	Overall Sentiment
Calliditas Therapeutics AB (publ)	Neutral
Legend Biotech	Positive

Summary

Legend Biotech beats Calliditas Therapeutics AB (publ) on 11 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Anbio Biotechnology?

Anbio Biotechnology (NASDAQ:NNNN) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both pharmaceutical products companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

Anbio Biotechnology has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ).

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anbio Biotechnology	$8.65M	273.31	$6.40M	N/A	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Anbio Biotechnology has a beta of 4.38, indicating that its share price is 338% more volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its share price is 77% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Anbio Biotechnology had 1 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 1 mentions for Anbio Biotechnology and 0 mentions for Calliditas Therapeutics AB (publ). Anbio Biotechnology's average media sentiment score of 1.89 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Anbio Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
Anbio Biotechnology	Very Positive
Calliditas Therapeutics AB (publ)	Neutral

Anbio Biotechnology has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Anbio Biotechnology's return on equity of 0.00% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anbio Biotechnology	N/A	N/A	N/A
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Anbio Biotechnology beats Calliditas Therapeutics AB (publ) on 9 of the 12 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, dividends, media sentiment, institutional ownership, valuation, risk, analyst recommendations and earnings.

In the previous week, Edgewise Therapeutics had 6 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 6 mentions for Edgewise Therapeutics and 0 mentions for Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ)'s average media sentiment score of 0.00 beat Edgewise Therapeutics' score of -0.14 indicating that Calliditas Therapeutics AB (publ) is being referred to more favorably in the news media.

Company	Overall Sentiment
Edgewise Therapeutics	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Edgewise Therapeutics. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Edgewise Therapeutics has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Edgewise Therapeutics' return on equity of -32.55% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Edgewise Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, indicating that its stock price is 77% more volatile than the broader market.

2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 21.3% of Edgewise Therapeutics shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Edgewise Therapeutics presently has a consensus price target of $44.22, indicating a potential upside of 34.33%. Given Edgewise Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Edgewise Therapeutics is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Summary

Edgewise Therapeutics beats Calliditas Therapeutics AB (publ) on 10 of the 16 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Erasca (NASDAQ:ERAS) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, valuation, analyst recommendations, institutional ownership, dividends, profitability, earnings and risk.

Erasca has a beta of 0.73, suggesting that its stock price is 27% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the broader market.

Calliditas Therapeutics AB (publ) has higher revenue and earnings than Erasca. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Erasca, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Erasca	N/A	N/A	-$124.55M	-$0.93	N/A
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

In the previous week, Erasca had 8 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 8 mentions for Erasca and 0 mentions for Calliditas Therapeutics AB (publ). Erasca's average media sentiment score of 0.93 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Erasca is being referred to more favorably in the media.

Company	Overall Sentiment
Erasca	Positive
Calliditas Therapeutics AB (publ)	Neutral

Erasca presently has a consensus target price of $20.11, indicating a potential upside of 50.42%. Given Erasca's stronger consensus rating and higher possible upside, equities research analysts clearly believe Erasca is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Erasca	1 Sell rating(s)	2 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.60
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

67.8% of Erasca shares are held by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. 14.2% of Erasca shares are held by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Erasca has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Erasca's return on equity of -35.31% beat Calliditas Therapeutics AB (publ)'s return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Erasca	N/A	-35.31%	-29.49%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Summary

Erasca beats Calliditas Therapeutics AB (publ) on 11 of the 15 factors compared between the two stocks.

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Indivior (NASDAQ:INDV) and Calliditas Therapeutics AB (publ) (NASDAQ:CALT) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

Indivior has a net margin of 19.44% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Calliditas Therapeutics AB (publ)'s return on equity of -212.04% beat Indivior's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Indivior	19.44%	-219.26%	29.40%
Calliditas Therapeutics AB (publ)	-30.18%	-212.04%	-27.96%

Indivior has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Calliditas Therapeutics AB (publ) has a beta of 1.77, meaning that its share price is 77% more volatile than the broader market.

In the previous week, Indivior had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Indivior and 0 mentions for Calliditas Therapeutics AB (publ). Indivior's average media sentiment score of 0.21 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Indivior is being referred to more favorably in the media.

Company	Overall Sentiment
Indivior	Neutral
Calliditas Therapeutics AB (publ)	Neutral

Indivior has higher earnings, but lower revenue than Calliditas Therapeutics AB (publ). Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Indivior, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Indivior	$1.24B	3.75	$210M	$1.95	19.53
Calliditas Therapeutics AB (publ)	$1.60B	0.74	-$43.96M	-$1.85	N/A

Indivior currently has a consensus price target of $39.33, indicating a potential upside of 3.26%. Given Indivior's stronger consensus rating and higher possible upside, equities analysts clearly believe Indivior is more favorable than Calliditas Therapeutics AB (publ).

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Indivior	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	3.00
Calliditas Therapeutics AB (publ)	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

60.3% of Indivior shares are owned by institutional investors. Comparatively, 2.8% of Calliditas Therapeutics AB (publ) shares are owned by institutional investors. 0.7% of Indivior shares are owned by company insiders. Comparatively, 2.2% of Calliditas Therapeutics AB (publ) shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Indivior beats Calliditas Therapeutics AB (publ) on 13 of the 17 factors compared between the two stocks.

Get Calliditas Therapeutics AB (publ) News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CALT vs. The Competition

Export

Metric	Calliditas Therapeutics AB (publ)	Pharmaceutical Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.19B	$766.79M	$6.50B	$11.95B
Dividend Yield	N/A	4.84%	2.67%	5.61%
P/E Ratio	-21.62	1.46	24.65	23.63
Price / Sales	0.74	129.13	503.21	104.15
Price / Cash	N/A	20.06	43.05	54.72
Price / Book	37.74	7.93	10.43	6.70
Net Income	-$43.96M	-$4.69M	$3.56B	$337.26M
7 Day Performance	N/A	-2.04%	-2.94%	-2.43%
1 Month Performance	N/A	3.96%	-0.39%	0.19%
1 Year Performance	N/A	93.62%	20.10%	23.15%

Calliditas Therapeutics AB (publ) Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CALT Calliditas Therapeutics AB (publ)	N/A	$40.00 flat	N/A	N/A	$1.19B	$1.60B	N/A	180
LEGN Legend Biotech	4.4046 of 5 stars	$36.28 +42.2%	$59.15 +63.0%	-7.4%	$4.74B	$1.03B	N/A	2,965	High Trading Volume
NNNN Anbio Biotechnology	1.5491 of 5 stars	$32.12 +6.5%	N/A	N/A	$4.34B	$8.65M	N/A	27	Positive News
EWTX Edgewise Therapeutics	2.3172 of 5 stars	$37.25 -7.5%	$44.22 +18.7%	+113.1%	$4.33B	N/A	N/A	60
ERAS Erasca	2.898 of 5 stars	$13.48 -2.5%	$18.75 +39.1%	+730.4%	$4.30B	N/A	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CALT) was last updated on 6/11/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. LEGN, NNNN, EWTX, ERAS, and INDV

How does Calliditas Therapeutics AB (publ) compare to Legend Biotech?

Summary

How does Calliditas Therapeutics AB (publ) compare to Anbio Biotechnology?

Summary

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Summary

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Summary

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Calliditas Therapeutics AB (publ) (CALT) Competitors

CALT vs. LEGN, NNNN, EWTX, ERAS, and INDV

How does Calliditas Therapeutics AB (publ) compare to Legend Biotech?

Which has stronger valuation and earnings, CALT or LEGN?

Is CALT or LEGN more profitable?

Do insiders & institutionals have more ownership in CALT or LEGN?

Do analysts recommend CALT or LEGN?

Which has more volatility and risk, CALT or LEGN?

Does the media prefer CALT or LEGN?

Summary

How does Calliditas Therapeutics AB (publ) compare to Anbio Biotechnology?

Which has higher valuation & earnings, NNNN or CALT?

Which has more volatility and risk, NNNN or CALT?

Do institutionals & insiders believe in NNNN or CALT?

Does the media refer more to NNNN or CALT?

Is NNNN or CALT more profitable?

Do analysts recommend NNNN or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Edgewise Therapeutics?

Does the media refer more to EWTX or CALT?

Which has preferable earnings and valuation, EWTX or CALT?

Is EWTX or CALT more profitable?

Which has more risk & volatility, EWTX or CALT?

Do institutionals and insiders believe in EWTX or CALT?

Do analysts recommend EWTX or CALT?

Summary

How does Calliditas Therapeutics AB (publ) compare to Erasca?

Which has more risk and volatility, ERAS or CALT?

Which has preferable earnings and valuation, ERAS or CALT?

Does the media favor ERAS or CALT?

Do analysts recommend ERAS or CALT?

Do institutionals & insiders believe in ERAS or CALT?

Is ERAS or CALT more profitable?

Summary

How does Calliditas Therapeutics AB (publ) compare to Indivior?

Is INDV or CALT more profitable?

Which has more risk and volatility, INDV or CALT?

Does the media refer more to INDV or CALT?

Which has higher earnings and valuation, INDV or CALT?

Do analysts prefer INDV or CALT?

Do institutionals & insiders believe in INDV or CALT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CALT vs. The Competition

Calliditas Therapeutics AB (publ) Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools